Klinisk Biokemi i Norden · 3 2016
| 15
rionic gonadotropin and pregnancy-associated
plasma protein-A. Ultrasound Obstet Gynecol
1999;13:231-7.
17. Lawrence JB, Oxvig C, Overgaard MT, Sot-
trup-Jensen L, Gleich GJ, Hays LG, et al. The
insulin-like growth factor (IGF)-dependent
IGF binding protein-4 protease secreted by
human fibroblasts is pregnancy-associated
plasma protein-A. Proc Natl Acad Sci U S A
1999;96:3149-53.
18. Dugoff L, Hobbins JC, Malone FD, Porter TF,
Luthy D, Comstock CH, et al. First-trimester
maternal serumPAPP-A and free-beta subunit
human chorionic gonadotropin concentrations
and nuchal translucency are associated with
obstetric complications: a population-based
screening study (the FASTER Trial). Am J
Obstet Gynecol 2004;191:1446-51.
19. Smith GC, Stenhouse EJ, Crossley JA, Aitken
DA, Cameron AD, Connor JM. Early preg-
nancy levels of pregnancy-associated plasma
protein a and the risk of intrauterine growth
restriction, premature birth, preeclampsia,
and stillbirth. J Clin Endocrinol Metab
2002;87:1762-7.
20. Levine RJ, Lam C, Qian C, Yu KF, Maynard
SE, Sachs BP, et al. Soluble endoglin and
other circulating antiangiogenic factors in pre-
eclampsia. N Engl J Med 2006;355:992-1005.
21. Levine RJ, Maynard SE, Qian C, LimKH, Eng-
land LJ, Yu KF, et al. Circulating angiogenic
factors and the risk of preeclampsia. N Engl J
Med 2004;350:672-83.
22. Saffer C, Olson G, Boggess KA, Beyerlein R,
Eubank C, Sibai BM. Determination of pla-
cental growth factor (PlGF) levels in healthy
pregnant women without signs or symp-
toms of preeclampsia. Pregnancy Hypertens
2013;3:124-32.
23. Nucci M, Poon LC, Demirdjian G, Darbouret
B, Nicolaides KH. Maternal serum placental
growth factor (PlGF) isoforms 1 and 2 at 11-13
weeks’ gestation in normal and pathological
pregnancies. Fetal Diagn Ther 2014;36:106-16.
24. Yang W, Ahn H, Hinrichs M, Torry RJ, Torry
DS. Evidence of a novel isoform of placenta
growth factor (PlGF-4) expressed in human
trophoblast and endothelial cells. J Reprod
Immunol 2003;60:53-60.
25. Akolekar R, Zaragoza E, Poon LC, Pepes S,
Nicolaides KH. Maternal serum placental
growth factor at 11 + 0 to 13 + 6 weeks of
gestation in the prediction of pre-eclampsia.
Ultrasound Obstet Gynecol 2008;32:732-9.
26. Park F, Russo K, Williams P, Pelosi M, Pud-
dephatt R, Walter M, et al. Prediction and pre-
vention of early-onset pre-eclampsia: impact of
aspirin after first-trimester screening. Ultra-
sound Obstet Gynecol 2015;46:419-23.
27. Akolekar R, de CJ, Foidart JM, Munaut C,
Nicolaides KH. Maternal plasma soluble
fms-like tyrosine kinase-1 and free vascular
endothelial growth factor at 11 to 13 weeks
of gestation in preeclampsia. Prenat Diagn
2010;30:191-7.
28. Aggarwal PK, Chandel N, Jain V, Jha V. The
relationship between circulating endothelin-1,
soluble fms-like tyrosine kinase-1 and soluble
endoglin in preeclampsia. J Hum Hypertens
2012;26:236-41.
29. Haggerty CL, Seifert ME, Tang G, Olsen J, Bass
DC, Karumanchi SA, et al. Second trimester
anti-angiogenic proteins and preeclampsia.
Pregnancy Hypertens 2012;2:158-63.
30. Rana S, Powe CE, Salahuddin S, Verlohren
S, Perschel FH, Levine RJ, et al. Angiogenic
factors and the risk of adverse outcomes in
women with suspected preeclampsia. Circu-
lation 2012;125:911-9.
31. Zeisler H, Llurba E, Chantraine F, Vatish
M, Staff AC, Sennstrom M, et al. Predictive
Value of the sFlt-1:PlGF Ratio in Women
with Suspected Preeclampsia. N Engl J Med
2016;374:13-22.
32. Akolekar R, Syngelaki A, Beta J, Kocylowski
R, Nicolaides KH. Maternal serum placental
protein 13 at 11-13 weeks of gestation in pre-
eclampsia. Prenat Diagn 2009;29:1103-8.
33. Odibo AO, Zhong Y, Goetzinger KR, Odibo L,
Bick JL, Bower CR, et al. First-trimester placen-
tal protein 13, PAPP-A, uterine artery Doppler
and maternal characteristics in the prediction
of pre-eclampsia. Placenta 2011;32:598-602.
